NTN Buzztime (NTN) Announces Proposed Reverse Stock Split Ratio and Anticipated Closing of Merger Mar 23, 2021 05:27PM
BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update Aug 8, 2019 04:05PM
AgeX Therapeutics Inc. (AGE) Announces Michael H. May to Board Aug 5, 2019 05:26PM
Regenerative Medicine Leader Michael H. May Joins AgeX Board of Directors Aug 5, 2019 05:14PM
BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019 Aug 1, 2019 08:00AM
View Older Stories

Jul 31, 2019 08:00AM BioTime Announces Name Change to Lineage Cell Therapeutics
Jul 11, 2019 08:01AM BioTime (BTX) Commences Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
Jul 11, 2019 08:00AM BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
Jul 9, 2019 08:00AM AgeX Therapeutics’ CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research
May 22, 2019 08:00AM BioTime Announces Appointment of General Counsel
May 15, 2019 04:05PM AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
May 1, 2019 08:00AM AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute
Apr 5, 2019 08:00AM AgeX Therapeutics to Present at Master Investor Show 2019
Apr 1, 2019 04:48PM AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update
Mar 22, 2019 07:00AM AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
Mar 21, 2019 07:00AM AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany
Mar 18, 2019 08:00AM BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
Mar 7, 2019 07:00AM LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration
Mar 4, 2019 08:00AM BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019
Feb 26, 2019 08:00AM BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
Feb 14, 2019 08:00AM BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
Jan 31, 2019 08:00AM AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
Jan 30, 2019 08:09AM BioTime (BTX) Confirms Affiliate Company OncoCyte (OCX) Reported Successful Results With DetermaVu Diagnostic Test for Lung Cancer
Jan 30, 2019 08:00AM BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
Jan 22, 2019 08:00AM AgeX Therapeutics’ CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
Jan 10, 2019 08:00AM LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market
Jan 9, 2019 08:00AM AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
Jan 7, 2019 08:19AM BioTime (BTX) Reports Exclusive Research & License Option Agreement with Orbit Biomedical Ltd. for OpRegen
Jan 7, 2019 08:00AM BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
Jan 4, 2019 08:00AM BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
Jan 2, 2019 08:00AM BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
Jan 2, 2019 07:00AM AgeX Therapeutics to Present at Biotech Showcase 2019
Dec 4, 2018 08:02AM BioTime (BTX) Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem Platform in Ischemic Stroke
Dec 4, 2018 08:00AM BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke
Nov 29, 2018 08:00AM BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018
Nov 29, 2018 08:00AM AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference
Nov 29, 2018 07:00AM AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American
Nov 28, 2018 08:00AM BioTime Announces Distribution of AgeX Therapeutics Shares
Nov 8, 2018 06:35AM BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
Nov 8, 2018 06:30AM BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update
Nov 6, 2018 04:30PM BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call
Nov 5, 2018 08:06AM BioTime (BTX) Secures Second Installment Payment of $10.8M From Juvenescence Ltd.
Nov 5, 2018 08:00AM BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.
Oct 30, 2018 08:00AM BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
Oct 29, 2018 08:00AM BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
Oct 25, 2018 08:00AM BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares
Oct 22, 2018 08:00AM BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th
Sep 27, 2018 07:00AM BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences
Sep 25, 2018 07:00AM BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies
Sep 21, 2018 07:00AM BioTime Warrants to Expire on October 1, 2018
Sep 18, 2018 07:09AM BioTime (BTX) Names Brian Culley as CEO
Sep 18, 2018 07:00AM BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
Sep 18, 2018 07:00AM BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
Sep 17, 2018 01:00AM BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders
Sep 4, 2018 06:55AM BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
View Older Stories